{"analyses":[{"ciLowerLimit":"0.16","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.28","estimateComment":"A hazard ratio \\<1 favors Osimertinib 80mg","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.001","paramType":"Hazard Ratio (HR)","paramValue":"0.21","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.8","upperLimit":"18.4","value":"16.0"},{"groupId":"OG001","lowerLimit":"5.2","upperLimit":"6.9","value":"6.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"140"}],"units":"Participants"}],"description":"Time from randomisation to first subsequent anti-cancer therapy (FST) following randomised treatment discontinuation, or death if no FST administered. Any patient not known to have died nor received any subsequent anti-cancer therapy (ST) was censored at the last time known not to have received ST, ie, the last follow-up visit this was confirmed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Daily single dose of Osimertinib 80mg","id":"OG000","title":"Osimertinib 80mg"},{"description":"Platinum-based doublet chemotherapy","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (All randomised patients)","reportingStatus":"POSTED","timeFrame":"From date of randomisation until time of final OS analysis, a median follow-up of 43 months","title":"Time to First Subsequent Therapy (TFST)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Months"}